Clinical Trial

Safety, Tolerability and Pharmacokinetics of Meloxicam Nanocrystal Injection in Healthy Subjects

Completed Phase 1
View on ClinicalTrials.gov →
Summary
Primary Objective：To compare the pharmacokinetic profiles between meloxicam nanocrystal injection (strength: 1 mL: 30 mg, Yangtze River Pharmaceutical Group Co., Ltd.) and the originator meloxicam nanocrystal injection (trade name: ANJESO®, strength: 1 mL: 30 mg, Baudax Bio Inc.) in healthy volunteers. Secondary Objective：To observe the safety and tolerability of meloxicam nanocrystal injection and ANJESO® in healthy volunteers.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-24.
Trial Details
NCT Number NCT06902090
Lead Sponsor Yangtze River Pharmaceutical Group Co., Ltd.
Conditions Pain
Enrollment 20 participants
Start Date 2023-07-05
Primary Completion 2023-07-25 (estimated)
Study Completion 2023-08-25 (estimated)
Updated on ClinicalTrials.gov 2026-06-29